Tove Henriksen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tove Henriksen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Andrew John Lees
The National Hospital, Queen Square and Reta Lila Weston Institute for Neurological Studies University College London, United Kingdom
2 shared publications - Harry Staines
Sigma Statistical Services, Balmullo KY16 0BD, UK
2 shared publications - Angelo Antonini
Parkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padua, Padua, Italy
1 shared publication - Claudia Trenkwalder
Department of Neurosurgery, University Medical Centre Goettingen and Centre of Parkinsonism and Movement Disorders, Elena Hospital, Kassel, Germany
1 shared publication Donna Lockhart
Britannia Pharmaceuticals Limited, Reading, UK
1 shared publication- Donna Lockhart
Britannia Pharmaceuticals Limited, Reading, UK
1 shared publication
Latest Publications
- Open Access
- 1 September 2023
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 130 (11) , 1475-1484
Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience
Subcutaneous apomorphine infusion is a device-aided therapy for Parkinson’s disease that can be considered when motor fluctuations become persistent and are no longer adequately controlled by oral/transdermal medication. Apomorphine infusion is less invasive than enteral levodopa, deep brain stimulation or focused ultrasound, and is often indicated even when neurosurgical approaches are contraindicated. This article aims to provide practical guidance for doctors and nurses initiating and treating patients with apomorphine infusion, and is based on both trial data and clinical experience from movement disorders specialists. A post hoc analysis of data from the TOLEDO randomized clinical trial of apomorphine infusion was conducted along with an analysis of ‘real world’ experience from 13 movement disorders specialists using a questionnaire that focused on starting patients on apomorphine infusion. Practical guidelines for starting treatment with apomorphine infusion are provided taking into consideration the regional disparities in healthcare. Apomorphine infusion is straightforward to administer but to be successful it requires concordance from the patient and family, and clinical support from an experienced team of doctors and nurses, particularly in the early months of treatment.
- 1 September 2023
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 130 (11) , 1475-1484
Open AccessPractical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience
Subcutaneous apomorphine infusion is a device-aided therapy for Parkinson’s disease that can be considered when motor fluctuations become persistent and are no longer adequately controlled by oral/transdermal medication. Apomorphine infusion is less invasive than enteral levodopa, deep brain stimulation or focused ultrasound, and is often indicated even when neurosurgical approaches are contraindicated. This article aims to provide practical guidance for doctors and nurses initiating and treating patients with apomorphine infusion, and is based on both trial data and clinical experience from movement disorders specialists. A post hoc analysis of data from the TOLEDO randomized clinical trial of apomorphine infusion was conducted along with an analysis of ‘real world’ experience from 13 movement disorders specialists using a questionnaire that focused on starting patients on apomorphine infusion. Practical guidelines for starting treatment with apomorphine infusion are provided taking into consideration the regional disparities in healthcare. Apomorphine infusion is straightforward to administer but to be successful it requires concordance from the patient and family, and clinical support from an experienced team of doctors and nurses, particularly in the early months of treatment.
- Open Access
- 8 June 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (6) , 525
Continuous Subcutaneous Apomorphine Infusion in Parkinson’s Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation
(1) Background: Subcutaneous apomorphine infusion (SCAI) is one of the three main treatment options for motor fluctuations in advanced Parkinson’s disease (PD). The adherence to SCAI is generally considered to be low due to adverse events and because it is perceived as a treatment option to be used for a limited period only. We evaluated the reasons for discontinuation of SCAI in relation to when patients stopped treatment. (2) Methods: We reviewed the medical records of PD patients treated with SCAI at a single center, capturing patient demographics and the reasons for cessation of SCAI. (3) Results: 101 patients were included in the analysis, with a median time on treatment of 6.34 years. The main reasons for stopping SCAI were adverse events, death, and dissatisfaction with treatment. In the first 6 years of treatment, the predominant side effects leading to discontinuation were somnolence and hallucinations. (4) Conclusions: We suggest that SCAI can be an effective long-term treatment option for advanced PD, but it requires careful patient selection, a high level of communication with the patient and carer, and rigorous monitoring of the effects of treatment and for any adverse events so they can be promptly managed.
- 8 June 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (6) , 525
Open AccessContinuous Subcutaneous Apomorphine Infusion in Parkinson’s Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation
(1) Background: Subcutaneous apomorphine infusion (SCAI) is one of the three main treatment options for motor fluctuations in advanced Parkinson’s disease (PD). The adherence to SCAI is generally considered to be low due to adverse events and because it is perceived as a treatment option to be used for a limited period only. We evaluated the reasons for discontinuation of SCAI in relation to when patients stopped treatment. (2) Methods: We reviewed the medical records of PD patients treated with SCAI at a single center, capturing patient demographics and the reasons for cessation of SCAI. (3) Results: 101 patients were included in the analysis, with a median time on treatment of 6.34 years. The main reasons for stopping SCAI were adverse events, death, and dissatisfaction with treatment. In the first 6 years of treatment, the predominant side effects leading to discontinuation were somnolence and hallucinations. (4) Conclusions: We suggest that SCAI can be an effective long-term treatment option for advanced PD, but it requires careful patient selection, a high level of communication with the patient and carer, and rigorous monitoring of the effects of treatment and for any adverse events so they can be promptly managed.
- Open Access
- 1 February 2021
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 83, 79-85
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study
- 1 February 2021
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 83, 79-85
Open AccessLong-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study
- 1 January 2012
- Published by Touch Medical Media, Ltd. in European Neurological Review
- Vol. 7 ((Suppl.1))
Managing for the Long-term – Strategies for Initiating and Maintaining Successful Continuous Dopaminergic Stimulation Treatment
There are many factors that may influence treatment choice in patients with Parkinson’s disease. While ‘inclusion’ criteria include the clinical need for short- and long-term improvement, there are some well defined contraindications to continuous dopaminergic stimulation (CDS) therapies, such as age, cognitive impairment, psychosis or severe orthostatic hypotension. These contraindications vary between CDS therapies and can help guide the choice of treatment. Patient preferences and the practicalities of the treatment modality also play an important part in the decision-making process. Treatment selection algorithms have been developed and presented, but they require refining and need to be expanded to include guidance on management decisions – for example, when initial CDS therapy fails. While more trial data are gathered and as management algorithms evolve, case studies continue to provide important information on practical aspects of CDS therapies.
- 1 January 2012
- Published by Touch Medical Media, Ltd. in European Neurological Review
- Vol. 7 ((Suppl.1))
Managing for the Long-term – Strategies for Initiating and Maintaining Successful Continuous Dopaminergic Stimulation Treatment
There are many factors that may influence treatment choice in patients with Parkinson’s disease. While ‘inclusion’ criteria include the clinical need for short- and long-term improvement, there are some well defined contraindications to continuous dopaminergic stimulation (CDS) therapies, such as age, cognitive impairment, psychosis or severe orthostatic hypotension. These contraindications vary between CDS therapies and can help guide the choice of treatment. Patient preferences and the practicalities of the treatment modality also play an important part in the decision-making process. Treatment selection algorithms have been developed and presented, but they require refining and need to be expanded to include guidance on management decisions – for example, when initial CDS therapy fails. While more trial data are gathered and as management algorithms evolve, case studies continue to provide important information on practical aspects of CDS therapies.
- 19 March 2007
- Vol. 169 (12) , 1120
[Day hospitals, a new concept in the management of parkinsonism. The Danish Movement Disorder Society].
- 19 March 2007
- Vol. 169 (12) , 1120
[Day hospitals, a new concept in the management of parkinsonism. The Danish Movement Disorder Society].